Skip to main content

Table 1 Pregnancy characteristics and safety rates of the 3 groups

From: Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission

 

Group A

Group B

Group C

P

Subjects, n

62

61

65

-

Age, y

28.9 ± 11.8

29.7 ± 9.8

27.5 ± 12.9

0.559

Infection duration, y

15.3 ± 10.9

16.1 ± 9.9

15.7 ± 11.5

0.919

Gravidity, n

1.8 ± 1.2

1.8 ± 1.1

1.8 ± 1.3

0.369

Delivery, n

1.1 ± 0.2

1.1 ± 0.1

1.1 ± 0.4

0.369

Gestational age, wk

39.0 ± 1.0

39.3 ± 1.2

39.2 ± 1.1

0.308

Adverse pregnancy, %

12.9(8/62)

11.4(7/61)

13.8(9/65)

0.923

Postparum hemorrhage, %

17.7(11/62)

14.7(9/61)

18.4(12/65)

0.844

Cesarean section, %

19.3(12/62)

16.4(10/61)

20.0(13/65)

0.859